2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
CNS
1
Conditions
Melanoma
7
Carcinoma, Renal Cell
4
Squamous Cell Carcinoma of Head and Neck
3
Neoplasm Metastasis
3
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Sarcoma
2
Recurrence
2
Lymphoma, Non-Hodgkin
2
Head and Neck Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Non-Small-Cell Lung
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Stomach Neoplasms
1
Skin Neoplasms
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Neuroblastoma
1
Neoplasms
1
Metastatic Castration-resistant Prostate Cancer
1
Medulloblastoma
1
Lymphoma
1
Leukemia, B-Cell
1
Leukemia
1
Kidney Neoplasms
1
Glioma
1
Ependymoma
1
Carcinoma, Merkel Cell
1
Advanced Cancer
1
Interventions
Cyclophosphamide
17
ofatumumab
14
fludarabine
11
Rituximab
11
ibrutinib
10
fludarabine phosphate
9
acalabrutinib
7
Lenalidomide
6
Bendamustine Hydrochloride
6
venetoclax
5
obinutuzumab
5
Vincristine
4
Mesna
4
Melphalan
4
Immunotherapy, Adoptive
4
pirtobrutinib
3
Whole-Body Irradiation
3
Mycophenolic Acid
3
Chlorambucil
3
Bortezomib
3
Alemtuzumab
3
spebrutinib
2
navitoclax
2
idelalisib
2
Tacrolimus
2
Tablets
2
Stem Cell Transplantation
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
KW-2478
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, B-Cell
×
bempegaldesleukin
×
Clear all
NCT04730349
2023-03-24
PIVOT IO 020
Bristol-Myers Squibb
Phase 1/2
Terminated
15 enrolled
14 charts